- Home
- GMHS vs KYTX Comparison
GMHS vs KYTX Comparison
Compare GMHS & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMHS
- KYTX
- Stock Information
- Founded
- GMHS N/A
- KYTX 2018
- Country
- GMHS China
- KYTX United States
- Employees
- GMHS N/A
- KYTX N/A
- Industry
- GMHS
- KYTX
- Sector
- GMHS
- KYTX
- Exchange
- GMHS NYSE
- KYTX NYSE
- Market Cap
- GMHS 106.1M
- KYTX 125.2M
- IPO Year
- GMHS N/A
- KYTX 2024
- Fundamental
- Price
- GMHS $1.19
- KYTX $1.86
- Analyst Decision
- GMHS
- KYTX Buy
- Analyst Count
- GMHS 0
- KYTX 5
- Target Price
- GMHS N/A
- KYTX $18.80
- AVG Volume (30 Days)
- GMHS 280.3K
- KYTX 298.8K
- Earning Date
- GMHS 01-01-0001
- KYTX 05-13-2025
- Dividend Yield
- GMHS N/A
- KYTX N/A
- EPS Growth
- GMHS 98.09
- KYTX N/A
- EPS
- GMHS 0.05
- KYTX N/A
- Revenue
- GMHS $145,236,749.00
- KYTX N/A
- Revenue This Year
- GMHS N/A
- KYTX N/A
- Revenue Next Year
- GMHS N/A
- KYTX N/A
- P/E Ratio
- GMHS $23.80
- KYTX N/A
- Revenue Growth
- GMHS N/A
- KYTX N/A
- 52 Week Low
- GMHS $0.96
- KYTX $1.79
- 52 Week High
- GMHS $17.49
- KYTX $22.44
- Technical
- Relative Strength Index (RSI)
- GMHS N/A
- KYTX 39.01
- Support Level
- GMHS N/A
- KYTX $1.81
- Resistance Level
- GMHS N/A
- KYTX $2.27
- Average True Range (ATR)
- GMHS 0.00
- KYTX 0.21
- MACD
- GMHS 0.00
- KYTX 0.02
- Stochastic Oscillator
- GMHS 0.00
- KYTX 16.33
About GMHS GAMEHAUS HOLDINGS INC
Gamehaus Holdings Inc is a technology-driven mobile game publishing company for small- and medium-sized game developers. It built a diverse game portfolio across multiple genres, including social casino, match, simulation, RPG, puzzle, and bingo, others, and distributes mobile games created by developer partners across a wide range of gaming markets, including in countries such as the U.S., the U.K., Australia, Germany, France, Canada, Brazil, Japan, and India, among others. The company offers a comprehensive package of services covering all aspects of the game life cycle, including (i) game development, (ii) screening and pre-publication testing, (iii) user acquisition, and (iv) monetization.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.